```html

Zoster‑Induced Eye Redness (Ocular Herpes Zoster)

What is Zoster‑induced eye redness?

Zoster‑induced eye redness, also known as ocular herpes zoster or herpes zoster ophthalmicus (HZO), occurs when the varicella‑zoster virus (VZV)—the same virus that causes chicken‑pox and shingles—reactivates in the ophthalmic branch of the trigeminal nerve. The reactivation produces a painful skin rash on the forehead, eyelid, or nose and can involve the surface of the eye, leading to redness, inflammation, and sometimes vision‑threatening complications.

Because the eye is a delicate organ, inflammation can affect the conjunctiva (the thin membrane covering the white of the eye), the cornea (the clear front surface), the iris, the retina, or the optic nerve. Early recognition and treatment are critical to prevent permanent damage.

Sources: Mayo Clinic; CDC; American Academy of Ophthalmology (AAO)

Common Causes

While the primary trigger is reactivation of VZV, several factors increase the likelihood of developing ocular involvement. Below are the most common precipitating conditions and risk factors:

• Previous chicken‑pox infection – VZV remains dormant in sensory ganglia for decades.
• Age ≥ 50 years – Immunosenescence makes reactivation more likely.
• Immunosuppression – HIV/AIDS, organ transplantation, chemotherapy, or long‑term corticosteroid use.
• Stress or trauma – Physical or emotional stress can trigger viral reactivation.
• Chronic ocular diseases – Conditions like dry eye, blepharitis, or prior ocular surgery may predispose the eye to infection once VZV spreads.
• Systemic diseases – Diabetes mellitus, malignancy, or autoimmune disorders.
• Vaccination status – Lack of shingles vaccination (e.g., Shingrix) increases risk.
• Neurological disease affecting trigeminal nerve – Prior facial nerve injury or neuropathy.
• Smoking – Impairs immune response and microcirculation to ocular tissues.
• Use of topical ocular steroids without antiviral coverage.

Identifying these risk factors helps clinicians gauge the probability of ocular involvement when a patient presents with a typical shingles rash.

Associated Symptoms

Eye redness is rarely an isolated finding in HZO. Patients often report a constellation of symptoms that may develop over hours to days:

• Severe unilateral facial pain preceding the rash (often described as burning or stabbing).
• Dermatologic rash – clusters of vesicles on the forehead, scalp, or tip of the nose (Hutchinson’s sign).
• Conjunctival injection – bright red eye due to inflammation of the conjunctiva.
• Photophobia – discomfort or pain with bright light.
• Blurred vision or decreased visual acuity.
• Eye tearing or discharge – may be watery or purulent if a secondary bacterial infection develops.
• Foreign‑body sensation or gritty feeling.
• Eye swelling (eyelid edema) and crusting.
• Corneal involvement – dendritic lesions, ulceration, or scarring.
• Neurological signs – headache, ptosis, or diplopia if cranial nerves are affected.

Presence of any ocular symptom alongside a shingles rash should prompt immediate ophthalmologic evaluation.

When to See a Doctor

Prompt medical attention can drastically reduce the risk of permanent vision loss. Seek care urgently if you notice:

• Redness, pain, or swelling of the eye that follows a shingles rash on the same side of the face.
• Vision changes such as blurriness, floaters, or loss of part of the visual field.
• Severe pain that does not improve with over‑the‑counter analgesics.
• Persistent fever, chills, or feeling generally unwell.
• Signs of a secondary bacterial infection (yellow/green discharge, increasing swelling).
• Any rash that involves the tip of the nose (Hutchinson’s sign) – a strong predictor of ocular involvement.

If you have a weakened immune system, underlying eye disease, or are over 60, do not wait for symptoms to worsen before seeking care.

Diagnosis

Clinicians combine a thorough history with a targeted eye exam. Typical steps include:

1. Clinical History

• Onset and progression of rash and eye symptoms.
• Recent illnesses, vaccinations, or immunosuppressive medications.
• Past ocular history (e.g., cataract surgery, glaucoma).

2. Physical Examination

• Visual acuity testing – baseline measurement of vision.
• Slit‑lamp examination – detailed view of the cornea, conjunctiva, and anterior chamber.
• Fluorescein staining – highlights corneal epithelial defects or dendritic lesions.
• Fundoscopic exam – evaluates retina and optic nerve for vasculitis or necrosis.

3. Laboratory & Imaging (when needed)

• Polymerase chain reaction (PCR) of tear fluid or lesion swab to confirm VZV.
• Serology – less commonly used, may help in atypical cases.
• OCT (Optical Coherence Tomography) – assesses corneal thickness and retinal layers.
• CT/MRI – reserved for suspected orbital cellulitis or cavernous sinus involvement.

Early ophthalmology referral is the standard of care, especially if any corneal involvement is suspected.

Treatment Options

Management aims to halt viral replication, control inflammation, protect the cornea, and preserve vision.

Antiviral Therapy

• Acyclovir 800 mg five times daily (or valacyclovir 1 g three times daily, famciclovir 500 mg three times daily) for 7–10 days. Oral agents are effective when started within 72 hours of rash onset.
• For severe ocular disease or immunocompromised patients, intravenous acyclovir 10 mg/kg every 8 hours may be required.

Corticosteroids

• Topical steroids (e.g., prednisolone acetate 1%) can reduce anterior segment inflammation but must be used only after antiviral coverage is established**.
• Systemic steroids (e.g., oral prednisone 60 mg daily taper) are sometimes added to reduce orbital inflammation, especially in cases of uveitis or optic neuritis. Evidence supports their use when combined with antivirals.

Adjunctive Eye‑Care

• Artificial tears – lubricate and promote healing of the corneal epithelium.
• Topical antibiotic ointment (e.g., erythromycin) to prevent secondary bacterial infection.
• Patching – may relieve photophobia while the cornea heals.
• Cycloplegic drops (e.g., atropine) for painful iris spasm or uveitis.

Follow‑up Care

• Initial ophthalmology follow‑up within 24–48 hours of diagnosis.
• Subsequent visits every 3–5 days until the cornea is clear and inflammation subsides.
• Long‑term monitoring for chronic complications such as corneal scarring, glaucoma, or neurotrophic keratitis.

Prevention Tips

While you cannot eliminate the latent virus, several strategies markedly reduce the risk of reactivation and ocular involvement:

• Shingles vaccination – Shingrix (recombinant zoster vaccine) is >90 % effective in adults ≥50 years and is recommended even for those with prior shingles.
• Maintain a healthy immune system:
  • Balanced diet rich in fruits, vegetables, and omega‑3 fatty acids.
  • Regular moderate exercise.
  • Adequate sleep (7–9 hours per night).
• Manage chronic illnesses (diabetes, hypertension) aggressively.
• Quit smoking – improves microvascular health of the eye.
• Promptly treat any skin shingles lesions on the face or scalp with antivirals to reduce the chance of spread to the eye.
• For immunocompromised patients, discuss prophylactic antiviral therapy with your specialist.
• Practice good hand hygiene and avoid touching facial lesions to limit secondary bacterial infection.

Emergency Warning Signs

• Sudden loss of vision or a rapid decline in visual acuity.
• Severe eye pain unrelieved by analgesics.
• Marked swelling of the eyelids or orbit (possible orbital cellulitis).
• Formation of a corneal ulcer that enlarges despite treatment.
• High fever (>38.5 °C / 101.3 °F) with rigors.
• Neurological changes such as facial droop, double vision, or severe headache.
• Persistent redness and discharge after 48 hours of antiviral therapy.

If any of these red flags appear, seek emergency medical care (e.g., go to the nearest emergency department or call emergency services).

Key Take‑aways

Zoster‑induced eye redness is a potentially sight‑threatening manifestation of shingles that demands rapid recognition and treatment. Early antiviral therapy combined with careful ophthalmologic monitoring dramatically lowers the risk of permanent visual loss. Vaccination, a healthy immune system, and prompt treatment of facial shingles are the most effective preventative measures. When in doubt, err on the side of caution and consult an eye specialist promptly.

References:

1. Mayo Clinic. “Herpes zoster ophthalmicus.” Accessed March 2024. https://www.mayoclinic.org
2. CDC. “Shingles (Herpes Zoster) – Prevention.” Updated 2023. https://www.cdc.gov/shingles
3. American Academy of Ophthalmology. “Herpes Zoster Ophthalmicus.” Clinical Practice Guidelines, 2022.
4. National Institutes of Health. “Varicella Zoster Virus: Epidemiology & Pathogenesis.” NIH Publication No. 2023‑04.
5. World Health Organization. “Shingles vaccine: WHO position paper.” 2021.
6. R. L. Goh et al., “Management of Herpes Zoster Ophthalmicus,” *Ophthalmology* 2020; 127(5): 714‑723.

```